A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study.

医学 人造眼泪 眼科 随机对照试验 干眼症 临床试验
作者
John D. Sheppard,David Wirta,Eugene B McLaurin,Blair E. Boehmer,Joseph B. Ciolino,Meides Alice,Thomas Schlüter,George W Ousler,Dale W. Usner,Sonja Krösser
出处
期刊:Cornea [Lippincott Williams & Wilkins]
卷期号:40 (10): 1290-1297
标识
DOI:10.1097/ico.0000000000002633
摘要

Dry eye disease (DED) is defined by the International Dry Eye Workshop (TFOS DEWS II) as a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles.1 In DED patients, activities requiring prolonged gazing with involuntary suppression of blinking can lead to ocular surface irregularities and corneal epithelium damage,2 both affecting visual function3 and eventually preventing patients from performing basic activities of daily life such as reading, driving, or working with screens.4 Consequently, DED negatively impacts quality of life comparable with other severe diseases.5 Recently, the impact of DED on reading speed has been increasingly investigated,6–11 suggesting that reading speed might be substantially affected by the level of corneal staining, especially under straining conditions in daily life such as prolonged duration of reading. The treatment under investigation, CyclASol 0.1%, is a clear topical water-free ophthalmic solution of cyclosporine A in a novel vehicle, the semifluorinated alkane (SFA)-based EyeSol technology, using the SFA perfluorobutylpentane (abbreviated F4H5). This topical formulation was developed for the treatment of DED with the goal of increasing local bioavailability, avoiding the use of oils, surfactants, and preservatives. Cyclosporine A is an antiinflammatory agent with immunomodulatory properties with proven efficacy in DED.12 Potential benefits of the CyclASol 0.1% formulation in a water-free SFA solution include improved tolerability and decreased visual disturbance compared with typical cyclosporine A formulations, which frequently involve surfactants and oils. A further potential benefit is an improved clinical efficacy because of better local bioavailability. CyclASol has been investigated previously in one phase 1 clinical study with healthy volunteers and one phase 2 clinical study in patients with DED. Both clinical studies showed an excellent tolerability and safety profile. The CyclASol phase 2 study was a randomized, double-masked, vehicle-controlled, dose finding study with CyclASol 0.05% and CyclASol 0.1% and an open-label active comparator and showed a consistent reduction in corneal and conjunctival staining after treatment with CyclASol compared with the vehicle and with the active comparator, with an early onset of effect as of week 2.13 The central area of the cornea, which is an important region relevant to visual function, benefitted most. Thus, reading assessments were included in the present phase 2B/3 study. The treatment effect on cornea staining parameters was more pronounced in patients with higher baseline values of total corneal fluorescein staining (CFS). Therefore, patients with total CFS scores ≥10 [National Eye Institute (NEI) scale] at baseline were chosen for the confirmatory clinical phase 2B/3 study. The 0.1% concentration was selected for its trend toward a better effect on symptoms in the target population. This work presents the results of the phase 2B/3 study CYS-003 (ESSENCE) designed to confirm the efficacy, safety, and tolerability of CyclASol 0.1% ophthalmic solution in comparison with its vehicle (F4H5) for the treatment of signs and symptoms of DED.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
巧可脆脆完成签到,获得积分10
刚刚
wwj发布了新的文献求助10
1秒前
oreo完成签到,获得积分10
1秒前
Juvenilesy的应助被1101592875采纳,获得10
1秒前
广东下不了一点雪完成签到,获得积分10
1秒前
whddue完成签到,获得积分10
2秒前
WWWJ完成签到,获得积分10
2秒前
chonghuang发布了新的文献求助10
2秒前
cdercder的应助被心房的锁采纳,获得30
2秒前
bkagyin的应助被ZM采纳,获得10
3秒前
小马甲的应助被科研通管家采纳,获得30
3秒前
interest-li完成签到,获得积分10
3秒前
bkagyin的应助被科研通管家采纳,获得10
3秒前
SHANELIU完成签到 ,获得积分10
3秒前
无花果的应助被科研通管家采纳,获得10
3秒前
爆米花的应助被科研通管家采纳,获得10
3秒前
hhh发布了新的文献求助10
4秒前
kayzhu完成签到,获得积分10
4秒前
4秒前
Maestro_S的应助被科研通管家采纳,获得10
4秒前
4秒前
今后的应助被科研通管家采纳,获得10
4秒前
FashionBoy的应助被科研通管家采纳,获得10
4秒前
4秒前
完美世界的应助被科研通管家采纳,获得10
4秒前
无花果的应助被科研通管家采纳,获得10
4秒前
4秒前
shangguang的应助被科研通管家采纳,获得10
4秒前
石及完成签到,获得积分10
5秒前
Hello的应助被科研通管家采纳,获得10
5秒前
5秒前
思源的应助被科研通管家采纳,获得10
5秒前
无极微光的应助被科研通管家采纳,获得20
5秒前
5秒前
5秒前
所所的应助被科研通管家采纳,获得10
5秒前
李爱国的应助被小明无敌采纳,获得10
5秒前
shang发布了新的文献求助10
5秒前
Lucas的应助被科研通管家采纳,获得10
5秒前
今后的应助被科研通管家采纳,获得10
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181279
求助须知:如何正确求助?哪些是违规求助? 9571198
关于积分的说明 21817073
捐赠科研通 7777612
什么是DOI,文献DOI怎么找? 3433454
关于科研通互助平台的介绍 2557692
邀请新用户注册赠送积分活动 2479519